Floatz logo

Cyclophosphamide

Recurrent Malignant Soft Tissue Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Malignant Soft Tissue Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 3B
Bms-907351
National Cancer Institute (NCI)
Phase 3B
Ipilimumab
National Cancer Institute (NCI)
Phase 3B
Enzalutamide
OHSU Knight Cancer Institute
Phase 2B
Ptvg-Hp
University of Wisconsin, Madison
Phase 1/2CCC
Pembrolizumab
University of Wisconsin, Madison
Phase 1/2CCC
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 1CC
Cord Blood-Derived Expanded Allogeneic Natural Killer Cells
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →